# Eli Lilly and Company (LLY) — Q1-2025 Earnings Results

**Report date:** 2025-05-01 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q1-2025

## Post-Earnings Brief

### Headline

Eli Lilly Misses on EPS, Stock Down 11.66%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.34 | N/A | -5.01% |

### Management Commentary

**Tone:** Defensive

Overall, management expressed concern over recent performance but highlighted their commitment to innovation. They did not provide specific guidance for the upcoming quarters.

**Key quotes:**

> Management acknowledged challenges in meeting earnings expectations.

> They emphasized ongoing investments in research and development.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Eli Lilly's earnings report indicates a slight miss on EPS, which contributed to a significant drop in stock price by 11.66%. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. Management's defensive tone suggests they are aware of the challenges ahead but remain focused on long-term growth through R&D investments.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q1-2025_